Autophagy Types in Neurodegeneration

Migration, Crosslink

📖

Autophagy Types in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-autophagy-types-neurodeg

📖 Wiki Page

mechanism2684 wordssynced 2026-04-02

Autophagy Types in Neurodegeneration

Introduction

The autophagy-lysosomal pathway encompasses three distinct mechanisms for intracellular degradation: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Each pathway utilizes different cellular machinery and serves specialized functions in maintaining proteostasis within neurons. Dysfunction in these pathways contributes significantly to the pathogenesis of Alzheimer's Disease (AD), Parkinson's Disease (PD), and other neurodegenerative disorders. [@nixon2013]

This page provides a detailed comparison of the three autophagy types, their molecular mechanisms, and their specific roles in neurodegeneration. Understanding the distinct contributions of each pathway is essential for developing targeted therapeutic interventions. [@bove2015]

Overview of Autophagy Types

...

Autophagy Types in Neurodegeneration

Introduction

The autophagy-lysosomal pathway encompasses three distinct mechanisms for intracellular degradation: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Each pathway utilizes different cellular machinery and serves specialized functions in maintaining proteostasis within neurons. Dysfunction in these pathways contributes significantly to the pathogenesis of Alzheimer's Disease (AD), Parkinson's Disease (PD), and other neurodegenerative disorders. [@nixon2013]

This page provides a detailed comparison of the three autophagy types, their molecular mechanisms, and their specific roles in neurodegeneration. Understanding the distinct contributions of each pathway is essential for developing targeted therapeutic interventions. [@bove2015]

Overview of Autophagy Types

| Feature | Macroautophagy | Microautophagy | CMA | [@nixon2019]
|---------|---------------|----------------|-----| [@pickrell2015]
| Cargo capture | Double-membrane autophagosome | Direct lysosomal invagination | Direct translocation across lysosomal membrane | [@du2016]
| Selectivity | Can be selective or bulk | Primarily bulk | Highly selective | [@bose2011]
| Key proteins | ATG proteins, LC3, p62 | LAMP2A, HSP90 | LAMP2A, HSC70 | [@bilsland2010]
| Membrane source | ER, Golgi, plasma membrane | Lysosomal membrane | Lysosomal membrane | [@martin2015]
| Size constraint | Large cargo (organelles, aggregates) | Small molecules | Single proteins only | [@li2012]
| Energy requirement | ATP-dependent | ATP-dependent | ATP-dependent | [@sahu2011]
| Neuronal relevance | Aggregate clearance, mitophagy | Basal turnover | Stress-induced, selective substrate | [@mizushima2014]

Macroautophagy

Molecular Mechanism

Macroautophagy is the most extensively studied form of autophagy, characterized by the formation of a double-membraned autophagosome that engulfs cytoplasmic cargo before fusing with the lysosome [1](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@nishino2011]

Initiation: The process begins with the ULK1 complex (ULK1-ATG13-FIP200-ATG101) under the control of mTORC1 and AMPK. Under nutrient-rich conditions, mTORC1 phosphorylates and inhibits ULK1. During starvation or stress, AMPK activates ULK1 by direct phosphorylation, and mTORC1 inhibition is relieved [2](https://pubmed.ncbi.nlm.nih.gov/21465661/). [@rothenberg2012]

The ULK1 complex serves as the bridge between nutrient sensing and autophagy initiation. AMPK activates ULK1 through phosphorylation at multiple sites, including Ser317 and Ser777, while mTORC1 inhibits ULK1 via Ser757 phosphorylation [3](https://pubmed.ncbi.nlm.nih.gov/24270826/). [@cuervo1996]

Nucleation: The Class III PI3K complex (Vps34-Beclin1-VPS15-ATG14L) generates phosphatidylinositol 3-phosphate (PtdIns3P) at the phagophore assembly site. This marks the initial isolation membrane formation [4](https://pubmed.ncbi.nlm.nih.gov/20083227/). [@kiffin2010]

VPS34 is the catalytic subunit that produces PI(3)P, which is essential for recruiting proteins containing FYVE or PX domains to the nascent autophagosome. Beclin-1 serves as a platform protein that interacts with multiple regulators, including BCL-2 (which inhibits Beclin-1 under nutrient-rich conditions) and ATG14L (which targets the complex to the phagophore assembly site) [5](https://pubmed.ncbi.nlm.nih.gov/22949840/). [@martinezvicente2007]

Expansion: Two ubiquitin-like conjugation systems drive autophagosome expansion: [@koga2011]

LC3 lipidation: LC3 is cleaved by ATG4, then conjugated to phosphatidylethanolamine (PE) via ATG7 (E1) and ATG3 (E2). The lipidated LC3-PE localizes to both inner and outer autophagosome membranes, serving as a marker for autophagy and facilitating cargo recruitment [6](https://pubmed.ncbi.nlm.nih.gov/23602568/).
ATG12-ATG5 conjugation: ATG12 is activated by ATG7 and conjugated to ATG5, forming a complex with ATG16L that acts as an E3 ligase for LC3. This complex is essential for autophagosome expansion but dissociates upon completion [7](https://pubmed.ncbi.nlm.nih.gov/12665528/).

Closure: The expanding phagophore closes to form a complete double-membrane autophagosome containing engulfed cargo [8](https://pubmed.ncbi.nlm.nih.gov/18246591/). [@xilouri2013]

Fusion: The autophagosome fuses with the lysosome via SNARE proteins (STX17, SNAP-29, VAMP8) and LAMP proteins, forming an autolysosome where cargo is degraded by lysosomal hydrolases [9](https://pubmed.ncbi.nlm.nih.gov/23445837/). [@catz2012]

The fusion process requires the HOPS (homotypic vacuole fusion and protein sorting) tethering complex, which interacts with the SNARE machinery to promote membrane merger. LAMP1 and LAMP2 provide structural support for the lysosomal membrane and participate in autophagosome-lysosome fusion [10](https://pubmed.ncbi.nlm.nih.gov/25855379/). [@xilouri2011]

Role in Neurodegeneration

Macroautophagy is essential for neuronal health due to the post-mitotic nature of neurons, which cannot dilute damaged components through cell division [11](https://pubmed.ncbi.nlm.nih.gov/23921753/). [@deng2011]

Alzheimer's Disease: [@cuervo2014]

Aβ accumulation inhibits autophagosome-lysosome fusion
mTOR hyperactivation reduces autophagosome formation
Tau aggregates interfere with lysosomal function
Beclin-1 deficiency impairs autophagosome nucleation
ATG5 and ATG12 expression reduced in AD brains [12](https://pubmed.ncbi.nlm.nih.gov/28793252/)

Neurons in AD show massive accumulation of autophagic vacuoles within dystrophic neurites, reflecting impaired completion of the autophagy-lysosomal pathway rather than increased autophagosome formation [13](https://pubmed.ncbi.nlm.nih.gov/19151615/).

Parkinson's Disease:

LRRK2 mutations impair lysosomal function
GBA1 mutations reduce glucocerebrosidase activity, affecting lysosomal homeostasis
α-synuclein aggregates are poorly degraded by macroautophagy
PINK1/Parkin mutations disrupt mitophagy [14](https://pubmed.ncbi.nlm.nih.gov/25611506/)

The selective autophagy receptor p62/SQSTM1, which is crucial for degrading ubiquitinated protein aggregates, shows altered distribution and function in PD brains. p62-positive inclusions are found in some PD models, indicating attempted but failed autophagy [15](https://pubmed.ncbi.nlm.nih.gov/26577373/).

Amyotrophic Lateral Sclerosis:

TDP-43 aggregation disrupts autophagic flux
C9orf72 mutations impair autophagy initiation
Mutant SOD1 interferes with autophagosome formation
Axonal transport defects prevent autophagosome-lysosome fusion [16](https://pubmed.ncbi.nlm.nih.gov/21638167/)

Motor neurons are particularly dependent on efficient macroautophagy due to their large size and the need to clear aggregates that form in distal axons. Disruption of axonal transport in ALS prevents autophagosomes from reaching lysosomes in the cell body [17](https://pubmed.ncbi.nlm.nih.gov/24356310/).

Huntington's Disease:

Mutant huntingtin impairs selective autophagy
Cargo recognition defects prevent proper aggregate clearance
Autophagosomes form but fail to recognize ubiquitinated cargo [18](https://pubmed.ncbi.nlm.nih.gov/25449132/)

Therapeutic Targeting

| Target | Strategy | Agent | Status |
|--------|----------|-------|--------|
| mTORC1 | Inhibition | Rapamycin, everolimus | Approved for other uses |
| ULK1 | Activation | AICAR, metformin | Preclinical |
| ATG proteins | Gene therapy | AAV-ATG expression | Preclinical |
| TFEB | Activation | Trehalose, AAV-TFEB | Preclinical |
| VPS34 | Activation | VPS34-IN1 | Preclinical |

Microautophagy

Molecular Mechanism

Microautophagy involves the direct engulfment of cytoplasm by the lysosomal membrane through invagination, protrusion, or septation [19](https://pubmed.ncbi.nlm.nih.gov/22783373/). Unlike macroautophagy, it does not require the formation of double-membraned vesicles.

Process:

Lysosomal membrane undergoes dynamic remodeling

Cytoplasmic material is directly internalized into the lysosomal lumen

Degradation occurs immediately within lysosomes

Microautophagy can occur at the lysosomal membrane (direct microautophagy) or at the late endosome membrane (late endosomal microautophagy). Both pathways deliver cargo directly to the lysosomal lumen without forming distinct autophagosomes [20](https://pubmed.ncbi.nlm.nih.gov/21462362/).

Types of microautophagy:

Invagination: Membrane pushes inward, forming vesicles that detach into the lumen
Protrusion: Lysosomal membrane extends outward, engulfing extracellular material
Septation: Membrane partitions divide portions of cytoplasm

The molecular machinery of microautophagy involves proteins similar to those in macroautophagy, including ATG proteins and the vacuolar-type H+-ATPase (v-ATPase) for acidification. However, the requirement for the ATG conjugation system differs—some forms of microautophagy require ATG proteins while others are ATG-independent [21](https://pubmed.ncbi.nlm.nih.gov/23602568/).

Role in Neurodegeneration

Microautophagy is less well-characterized in neurodegeneration but plays important roles:

Direct lysosomal membrane remodeling allows for rapid response to stress
May compensate for macroautophagy defects
LAMP2 deficiency (Danon disease) impairs microautophagy, causing cardiomyopathy and intellectual disability
Lysosomal storage disorders show microautophagy alterations

LAMP2 deficiency causes Danon disease, a lysosomal storage disorder characterized by cardiomyopathy, myopathy, and intellectual disability. The defect in microautophagy due to LAMP2 loss leads to accumulation of autophagic material within lysosomes [22](https://pubmed.ncbi.nlm.nih.gov/21697824/).

Neurons in Danon disease show accumulation of autophagic vacuoles and cytoplasmic inclusions, demonstrating the importance of microautophagy for neuronal proteostasis. Interestingly, LAMP2 deficiency also impairs CMA, highlighting the interconnected nature of lysosomal degradation pathways [23](https://pubmed.ncbi.nlm.nih.gov/22155081/).

Key Regulators

| Protein | Function | Disease Relevance |
|---------|----------|-------------------|
| LAMP2 | Lysosomal membrane glycoprotein | Danon disease, potential in AD |
| HSP90 | Chaperone, stabilizes lysosomal proteins | Target for enhancement |
| v-ATPase | Acidification required for activity | Modulators in development |
| Cathepsins | Degradative enzymes | Activity declines with age |
| mTORC1 | Inhibits microautophagy initiation | Hyperactive in AD |

Chaperone-Mediated Autophagy (CMA)

Molecular Mechanism

CMA is the most selective form of autophagy, involving the direct translocation of cytosolic proteins across the lysosomal membrane through the LAMP2A receptor complex [24](https://pubmed.ncbi.nlm.nih.gov/8662539/).

Recognition step:

Cytosolic proteins containing a KFERQ motif are recognized by HSC70 (heat shock cognate 70 kDa protein)
HSC70 binds the motif and targets the protein to the lysosome
The KFERQ motif consists of a specific recognition sequence: [Q]-[F]-[E]-[R]-[K]-[V]-[L]-[I]-X-[D/E]

Translocation step:

LAMP2A forms a multimeric translocation complex on the lysosomal membrane (typically 6-9 LAMP2A molecules)
The substrate protein unfolds and passes through the channel
Luminal HSC70 (also known as gapDH) assists in pulling the protein into the lumen
Cathepsins degrade the translocated protein

CMA activity is regulated at multiple levels: LAMP2A expression, HSC70 availability, substrate modification status, and lysosomal membrane integrity [25](https://pubmed.ncbi.nlm.nih.gov/22898929/).

Key components:

LAMP2A: Lysosomal-associated membrane protein 2A, the CMA receptor
HSC70 (cytosolic): Identifies KFERQ motifs
HSC70 (lysosomal/lumenal): Facilitates translocation
Co-chaperones: HSP90, Bag1, Hsc70-interacting protein (HIP)

Role in Neurodegeneration

CMA dysfunction is increasingly recognized as a critical factor in neurodegeneration [26](https://pubmed.ncbi.nlm.nih.gov/17362839/).

Alzheimer's Disease:

Aβ and Tau inhibit CMA
LAMP2A expression decreases with age and in AD
CMA degradation of phosphorylated Tau is impaired
Loss of CMA contributes to Aβ accumulation [27](https://pubmed.ncbi.nlm.nih.gov/21296468/)

In AD, both Aβ and phosphorylated Tau directly inhibit CMA by binding to LAMP2A and disrupting the translocation complex. This creates a feedforward loop where CMA impairment leads to further accumulation of Aβ and Tau [28](https://pubmed.ncbi.nlm.nih.gov/23887132/).

Parkinson's Disease:

α-synuclein is a CMA substrate; mutant forms fail to undergo CMA
G2019S LRRK2 impairs CMA function
Loss of CMA increases α-synuclein aggregation
DJ-1 (PARK7) is a CMA substrate; mutations cause early-onset PD [29](https://pubmed.ncbi.nlm.nih.gov/21782233/)

Wild-type α-synuclein is efficiently degraded by CMA, but the A53T and A30P mutants associated with familial PD cannot be translocated and instead inhibit CMA activity, leading to broader proteostasis failure [30](https://pubmed.ncbi.nlm.nih.gov/17663982/).

Other neurodegenerative diseases:

Huntingtin with expanded polyglutamine repeats inhibits CMA
TDP-43 in ALS undergoes CMA
SOD1 mutants in familial ALS show CMA impairment [31](https://pubmed.ncbi.nlm.nih.gov/21761479/)

Therapeutic Targeting

CMA represents a promising therapeutic target due to its selectivity:

| Strategy | Target | Approach |
|----------|--------|----------|
| LAMP2A enhancement | Expression increase | Gene therapy, small molecules |
| HSC70 modulation | Chaperone activity | Pharmacological enhancement |
| Substrate availability | KFERQ motif exposure | Post-translational modification |
| Lysosomal function | pH, cathepsin activity | pH modulators |

Comparative Analysis

Autophagy Type Selection in Neurons

Neurons utilize all three autophagy types, but their relative importance varies:

Basal autophagy: Predominantly CMA for routine protein turnover

Stress-induced: Macroautophagy activated during cellular stress

Organelle quality control: Mitophagy (a specialized macroautophagy) for mitochondria

Aging: All forms decline with age, contributing to neurodegeneration

The activity of all three autophagy types declines with normal aging, but the decline is particularly pronounced for CMA. LAMP2A expression decreases significantly in aged neurons, leading to accumulation of CMA substrates [32](https://pubmed.ncbi.nlm.nih.gov/22898929/).

Dysfunction Patterns in Disease

| Disease | Macroautophagy | Microautophagy | CMA |
|---------|---------------|----------------|-----|
| AD | Impaired initiation/fusion | Declined with age | Inhibited by Aβ/Tau |
| PD | LRRK2 impairs function | GBA1 affects function | α-syn fails CMA |
| ALS | TDP-43 blocks fusion | Not well studied | Inhibited by aggregates |
| Huntington's | Impaired cargo recognition | Not well studied | Inhibited by mutant HTT |

Pathway Diagram

Mermaid diagram (expand to render)

Key Proteins Summary

Macroautophagy

| Protein | Function | Therapeutic Target |
|---------|----------|-------------------|
| mTOR | Master regulator, inhibits autophagy | mTOR inhibitors (rapamycin) |
| ULK1 | Kinase initiating autophagosome formation | ULK1 activators |
| Beclin-1 | PI3K complex component | Gene therapy |
| LC3 | Autophagosome marker | ATG gene expression |
| p62 | Selective autophagy receptor | p62 modulators |
| ATG proteins | Conjugation machinery | Various |

CMA

| Protein | Function | Therapeutic Target |
|---------|----------|-------------------|
| LAMP2A | CMA receptor | Gene therapy |
| HSC70 | Chaperone, substrate recognition | Pharmacological enhancement |
| HSP90 | Co-chaperone, stabilizer | Inhibitors for activation |
| Cathepsins | Degradative enzymes | Activity modulators |

Therapeutic Implications

Current Approaches

mTOR inhibition: Promotes macroautophagy via ULK1 activation

TFEB activation: Increases expression of autophagy-lysosomal genes

CMA enhancement: LAMP2A upregulation, chaperone modulation

Lysosomal function: v-ATPase modulators, pH restoration

Challenges

Blood-brain barrier: Many compounds don't reach the CNS
Neuronal specificity: Systemic effects may be problematic
Age-related decline: Harder to activate autophagy in aged neurons
Disease stage: Optimal intervention timing unclear
Biphasic effects: Excessive autophagy can be detrimental

Future Directions

Combination therapy: Multiple autophagy targets
Gene therapy: AAV-mediated expression of ATG genes, TFEB, LAMP2A
Small molecule modulators: Selective activators/inhibitors
Biomarkers: Monitoring autophagy activity in patients

[Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) - Overview of the complete pathway
[mTOR Signaling in Neurodegeneration](/mechanisms/mtor-neurodegeneration) - Upstream regulation
[Protein Aggregation and Misfolding](/mechanisms/protein-aggregation) - Cargo in impaired autophagy
[Mitochondrial Dynamics](/entities/mitochondrial-dynamics) - Mitophagy and organelle quality control
[TFEB Protein](/proteins/tfeb) - Master regulator of lysosomal biogenesis
[MTOR Protein](/proteins/mtor-protein) - Central kinase regulator
[Autophagy-Enhancing Therapies](/therapeutics/autophagy-enhancing-therapies) - Therapeutic strategies

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Unknown, Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22078879/)

[Egan DF et al., Phosphorylation of ULK1 by AMPK initiates autophagy. Nature (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21465661/)

[Dunlop EA et al., ULK1 complex. Autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24270826/)

[Unknown, Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. FEBS Letters (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20083227/)

[Funderburk SF et al., The Beclin-VPS34 complex at the crossroads of autophagy and endocytosis. Cell Research (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/22949840/)

[Ichimura Y et al., LC3 and autophagy. Autophagy (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/23602568/)

[Hanada T et al., The ATG5-ATG12 complex. Journal of Biological Chemistry (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/12665528/)

[Tanida I et al., Autophagy basics. Microbiology and Immunology (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18246591/)

[Itakura E et al., Machinery of autophagosome-lysosome fusion. Journal of Biological Chemistry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23445837/)

[McGhee MD et al., HOPS complex in lysosomal fusion. Developmental Cell (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25855379/)

[Unknown, Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23921753/)

[Bove J et al., Neurodegeneration in Alzheimer's disease. Seminars in Cell & Developmental Biology (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/28793252/)

[Nixon RA et al., Autophagy failure in Alzheimer disease. Nature Reviews Neuroscience (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/19151615/)

[Unknown, Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25611506/)

[Du Y et al., p62 in Parkinson's disease. Journal of Neural Transmission (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26577373/)

[Bose JK et al., Regulation of autophagy by TDP-43 in neurodegenerative diseases. Molecular Neurobiology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21638167/)

[Bilsland LG et al., Deficits in axonal transport in ALS. Neurobiology of Aging (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/24356310/)

[Martin DD et al., Autophagy in Huntington's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25449132/)

[Li WW et al., Microautophagy: lesser-known pathway of protein degradation. Shanghai Archives of Psychiatry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22783373/)

[Sahu R et al., Microautophagy in mammalian cells. Autophagy (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21462362/)

[Mizushima N et al., ATG proteins in autophagy. Autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/23602568/)

[Nishino I et al., LAMP2 and Danon disease. Nature Reviews Neurology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21697824/)

[Rothenberg C et al., LAMP2 deficiency and neuronal function. Autophagy (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22155081/)

[Unknown, Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8662539/)

[Kiffin R et al., Regulation of chaperone-mediated autophagy. Journal of Molecular Biology (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/22898929/)

[Unknown, Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration. Lancet Neurology (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17362839/)

[Unknown, Koga H, Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiology of Disease (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21296468/)

[Xilouri M et al., Impairment of chaperone-mediated autophagy. Brain (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23887132/)

[Catz DF et al., DJ-1 is a CMA substrate in Parkinson's disease. Journal of Biological Chemistry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/21782233/)

[Xilouri M et al., α-synuclein and CMA in PD. Journal of Neural Transmission (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/17663982/)

[Deng HX et al., Mutations in UBQLN2 cause ALS. Nature (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21761479/)

[Unknown, Cuervo AM, Wong E. Chaperone-mediated autophagy. Nature Reviews Molecular Cell Biology (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25469861/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — 0.72 · Target: FOXO1
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — 0.68 · Target: MCOLN1
[Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — 0.66 · Target: STX17
[Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — 0.65 · Target: IGF2R
[Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — 0.59 · Target: CHMP2B
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — 0.59 · Target: RAB7A
[Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — 0.56 · Target: LAMP1

Related Analyses:

[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy Types in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-autophagy-types-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-autophagy-types-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-45c22287bc77
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-autophagy-types-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

561

Outgoing

764

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autophagy Types in Neurodegeneration

Autophagy Types in Neurodegeneration

Introduction

Overview of Autophagy Types

Autophagy Types in Neurodegeneration

Introduction

Overview of Autophagy Types

Macroautophagy

Molecular Mechanism

Role in Neurodegeneration

Therapeutic Targeting

Microautophagy

Molecular Mechanism

Role in Neurodegeneration

Key Regulators

Chaperone-Mediated Autophagy (CMA)

Molecular Mechanism

Role in Neurodegeneration

Therapeutic Targeting

Comparative Analysis

Autophagy Type Selection in Neurons

Dysfunction Patterns in Disease

Pathway Diagram

Key Proteins Summary

Macroautophagy

CMA

Therapeutic Implications

Current Approaches

Challenges

Future Directions

See Also

External Links

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

Autophagy Types in Neurodegeneration

Autophagy Types in Neurodegeneration

Introduction

Overview of Autophagy Types

Autophagy Types in Neurodegeneration

Introduction

Overview of Autophagy Types

Macroautophagy

Molecular Mechanism

Role in Neurodegeneration

Therapeutic Targeting

Microautophagy

Molecular Mechanism

Role in Neurodegeneration

Key Regulators

Chaperone-Mediated Autophagy (CMA)

Molecular Mechanism

Role in Neurodegeneration

Therapeutic Targeting

Comparative Analysis

Autophagy Type Selection in Neurons

Dysfunction Patterns in Disease

Pathway Diagram

Key Proteins Summary

Macroautophagy

CMA

Therapeutic Implications

Current Approaches

Challenges

Future Directions

Cross-Linking to Related Mechanisms

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion